{"id":30426,"date":"2017-05-29T16:54:17","date_gmt":"2017-05-29T15:54:17","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=30426"},"modified":"2017-05-29T16:54:17","modified_gmt":"2017-05-29T15:54:17","slug":"eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","title":{"rendered":"Herramientas para el seguimiento del paciente renal desde la farmacia comunitaria"},"content":{"rendered":"<p>El pasado mes de mayo,\u00a0 <strong>Alberto Mart\u00ednez-Castelao<\/strong>, m\u00e9dico especialista del Hospital de Bellvitge, <strong>Pere Trav\u00e9<\/strong>, especialista en Bioqu\u00edmica Cl\u00ednica, y las farmac\u00e9uticas <strong>Marian March<\/strong> y<strong> Dra. M. \u00c0ngels V\u00eda<\/strong>, presentaron la \u201c<b>Gu\u00eda consensuada por el ajuste de dosis de medicamentos en pacientes con insuficiencia renal<\/b>\u201d, consensuada entre el Grupo de Farmacia Pr\u00e1ctica de la Universidad de Barcelona y la <a href=\"http:\/\/www.sen.es\/\" target=\"_blank\" rel=\"noopener\">Sociedad Espa\u00f1ola de Nefrolog\u00eda (<\/a>SEN) en un acto que acogi\u00f3 al COFB, moderado por la vocal de la Junta del Colegio y responsable de la Comisi\u00f3n Delegada de Formaci\u00f3n,<strong> Aina Surroca.<\/strong> Los responsables de este documento presentaron la problem\u00e1tica de la enfermedad renal y mostraron las acciones llevadas a cabo en los \u00faltimos a\u00f1os desde la SEN para avanzar en el cribado y detecci\u00f3n de la enfermedad. &quot;La sesi\u00f3n tambi\u00e9n permiti\u00f3 adquirir las habilidades para su uso en las actividades farmac\u00e9uticas orientadas a la implementaci\u00f3n de servicios farmac\u00e9uticos relacionados con el uso seguro de los medicamentos&quot; explica Surroca.<\/p>\n<figure id=\"attachment_30435\" aria-describedby=\"caption-attachment-30435\" style=\"width: 610px\" class=\"wp-caption aligncenter\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-4.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-30435\" alt=\"guia-insuficiencia renal COFB (4)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-4.jpg\" width=\"610\" height=\"257\" \/><\/a><figcaption id=\"caption-attachment-30435\" class=\"wp-caption-text\">De izquierda a derecha: M. \u00c0ngels Via, Marian March, Aina Surroca, Pere Trav\u00e9 y Alberto Mart\u00ednez-Castelao<\/figcaption><\/figure>\n<div class=\"box shadow\"> <strong>La funci\u00f3n asistencial del farmac\u00e9utico est\u00e1 dirigida<\/strong>, entre otros aspectos, en <strong>evitar o limitar los potenciales efectos nefrot\u00f3xicos que tienen determinados medicamentos.<\/strong> Las principales precauciones para evitar la aparici\u00f3n de estos efectos nefrot\u00f3xicos son:<\/p>\n<ul>\n<li>Conocer qu\u00e9 f\u00e1rmacos son nefrot\u00f3xicos y el tipo de nefropat\u00eda que producen, a fin de poder identificar r\u00e1pidamente los s\u00edntomas caracter\u00edsticos.<\/li>\n<li>Valorar si existe otro f\u00e1rmaco de similar eficacia, con menor riesgo de nefrotoxicidad.<\/li>\n<li>Identificar y corregir, si cabe, los factores de riesgo que facilitan la aparici\u00f3n de nefrotoxicidad inducida por f\u00e1rmacos<\/li>\n<li>Si es necesario utilizar un f\u00e1rmaco con potencial nefrot\u00f3xico, realizar controles peri\u00f3dicos de la funci\u00f3n renal.<\/li>\n<li>Ajustar las dosis del f\u00e1rmaco seg\u00fan la tasa de filtraci\u00f3n glomerular para evitar su acumulaci\u00f3n: reducir la dosis o prolongar el intervalo interdosis.<\/li>\n<li>Adem\u00e1s, tambi\u00e9n es importante la funci\u00f3n del farmac\u00e9utico para evitar o reducir los potenciales efectos que la insuficiencia renal puede producir sobre la farmacocin\u00e9tica de los medicamentos que pueda estar utilizando o vaya a utilizar el paciente.<\/li>\n<\/ul>\n<p>Fuente: <a href=\"http:\/\/www.portalfarma.com\/Profesionales\/consejoinforma\/Paginas\/El-farmaceutico-crucial-en-prevencion-enfermedad-renal.aspx\" target=\"_blank\" rel=\"noopener\">Portalfarma <\/a><\/div>\n<figure id=\"attachment_30432\" aria-describedby=\"caption-attachment-30432\" style=\"width: 268px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-1.jpg\"><img decoding=\"async\" class=\"wp-image-30432\" alt=\"guia-insuficiencia renal COFB (1)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-1.jpg\" width=\"268\" height=\"179\" \/><\/a><figcaption id=\"caption-attachment-30432\" class=\"wp-caption-text\">Aina Surroca<\/figcaption><\/figure>\n<figure id=\"attachment_30434\" aria-describedby=\"caption-attachment-30434\" style=\"width: 268px\" class=\"wp-caption alignright\"><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-3.jpg\"><img decoding=\"async\" class=\"wp-image-30434\" alt=\"guia-insuficiencia renal COFB (3)\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2017\/05\/guia-insuficiencia-renal-COFB-3.jpg\" width=\"268\" height=\"179\" \/><\/a><figcaption id=\"caption-attachment-30434\" class=\"wp-caption-text\">Pere Trav\u00e9<\/figcaption><\/figure>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Informaci\u00f3n relacionada, publicada previamente en el Blog:<\/strong><\/p>\n<ul>\n<li><a href=\"http:\/\/blog.cofb.cat\/seguiment-del-pacient-diabetic-tipus-ii-a-la-farmacia-comunitaria\/\" target=\"_blank\" rel=\"noopener\">Seguimiento del paciente diab\u00e9tico tipo II en la farmacia comunitaria<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/atencio-farmaceutica-en-insuficiencia-renal\/\" target=\"_blank\" rel=\"noopener\">Atenci\u00f3n farmac\u00e9utica en insuficiencia renal<\/a><\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/insuficiencia-renal-associada-a-vih-un-dels-temes-del-nou-numero-de-circular-farmaceutica\/\" target=\"_blank\" rel=\"noopener\">La eliminaci\u00f3n del sarampi\u00f3n, farmacoterapia y m\u00e1s al nuevo n\u00famero de Circular Farmac\u00e9utica (1er trimestre 2014) <\/a>\u2013 Farmasistencia: Insuficiencia renal asociada a VIH<\/li>\n<li><a href=\"http:\/\/blog.cofb.cat\/els-farmaceutics-aprenen-a-controlar-pacients-polimedicats-amb-insuficiencia-renal\/\" target=\"_blank\" rel=\"noopener\">Los farmac\u00e9uticos aprenden a controlar pacientes polimedicados con insuficiencia renal<\/a><\/li>\n<\/ul>\n<p><strong>Quiz\u00e1s tambi\u00e9n te interesa:<\/strong><\/p>\n<p><strong><a href=\"http:\/\/www.ub.edu\/medicamentoseninsuficienciarenal\/\" target=\"_blank\" rel=\"noopener\">Acceso a la Gu\u00eda,<\/a> v\u00eda UB<\/strong><\/p>\n<p><a href=\"http:\/\/www.portalfarma.com\/Profesionales\/consejoinforma\/Paginas\/El-farmaceutico-crucial-en-prevencion-enfermedad-renal.aspx\" target=\"_blank\" rel=\"noopener\">El farmac\u00e9utico crucial en la prevenci\u00f3n de la enfermedad renal <\/a>(v\u00eda Portalfarma)<br \/>\n<a href=\"http:\/\/medicaments.gencat.cat\/ca\/ciutadania\/informacio-i-consells\/persones-i-medicaments\/insuficiencia-renal\/\" target=\"_blank\" rel=\"noopener\">Insuficiencia renal<\/a> (v\u00eda Departamento de Salud)<\/p>","protected":false},"excerpt":{"rendered":"<p>El pasado mes de mayo, Alberto Mart\u00ednez-Castelao, m\u00e9dico especialista del Hospital de Bellvitge, Pere Trav\u00e9, especialista en Bioqu\u00edmica Cl\u00ednica, y las farmac\u00e9uticas Marian March y Dra. M. \u00c0ngels V\u00eda, presentaron la \u201cGu\u00eda consensuada por el ajuste de dosis de medicamentos en pacientes con insuficiencia renal\u201d, consensuada entre el Grupo de [\u2026]<\/p>","protected":false},"author":1,"featured_media":30433,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[2787,69,2788,70,2789,2197,2790,45,2791],"class_list":["post-30426","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-efectes-nefrotoxics","tag-farmacia-comunitaria","tag-farmacocinetica","tag-formacio","tag-funcio-renal","tag-insuficiencia-renal","tag-malaltia-renal","tag-medicaments","tag-nefrotoxicitat"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria<\/title>\n<meta name=\"description\" content=\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\" \/>\n<meta property=\"og:description\" content=\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-05-29T15:54:17+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\",\"datePublished\":\"2017-05-29T15:54:17+00:00\",\"dateModified\":\"2017-05-29T15:54:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\"},\"wordCount\":533,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"efectes nefrot\u00f2xics\",\"farm\u00e0cia comunit\u00e0ria\",\"farmacocin\u00e9tica\",\"Formaci\u00f3\",\"funci\u00f3 renal\",\"insufici\u00e8ncia renal\",\"malaltia renal\",\"medicaments\",\"nefrotoxicitat\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\",\"name\":\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2017-05-29T15:54:17+00:00\",\"dateModified\":\"2017-05-29T15:54:17+00:00\",\"description\":\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","description":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","og_locale":"es_ES","og_type":"article","og_title":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","og_description":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","og_url":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2017-05-29T15:54:17+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","datePublished":"2017-05-29T15:54:17+00:00","dateModified":"2017-05-29T15:54:17+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/"},"wordCount":533,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","keywords":["efectes nefrot\u00f2xics","farm\u00e0cia comunit\u00e0ria","farmacocin\u00e9tica","Formaci\u00f3","funci\u00f3 renal","insufici\u00e8ncia renal","malaltia renal","medicaments","nefrotoxicitat"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","url":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/","name":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","datePublished":"2017-05-29T15:54:17+00:00","dateModified":"2017-05-29T15:54:17+00:00","description":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2017\/05\/29\/eines-pel-seguiment-del-pacient-renal-des-de-la-farmacia-comunitaria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Eines pel seguiment del pacient renal des de la farm\u00e0cia comunit\u00e0ria"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat mes de maig,\u00a0 Alberto Mart\u00ednez-Castelao, metge especialista de l\u2019Hospital de Bellvitge, Pere Trav\u00e9, especialista en Bioqu\u00edmica Cl\u00ednica, i les farmac\u00e8utiques Marian March i Dra. M. \u00c0ngels V\u00eda, van presentar la \u201cGuia consensuada per l\u2019ajust de dosi de medicaments en pacients amb insufici\u00e8ncia renal\u201d, consensuada entre el Grup de [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/30426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=30426"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/30426\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=30426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=30426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=30426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}